
Earlier today, we published our Q3 2026 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made the last 90 days and where we will focus for the rest of the year. Find out more: spr.ly/6011BHaJ3B

Health for All, Hunger for None. That’s what drives us at Bayer.

Earlier today, we published our Q3 2026 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made the last 90 days and where we will focus for the rest of the year. Find out more: spr.ly/6011BHaJ3B

Pharmaceuticals drives growth: Bayer increases sales and EBITDA before special items in third quarter of 2026, improves full-year outlook Here's our digital quarterly statement: spr.ly/6014BHa1ka

#NEWS: China’s Center of Drug Evaluation (CDE) has granted approval for our new drug for stroke risk reduction, following Priority Review. bayer.com/media/en-us/asunde…

NEW: A Bayer-commissioned report, with analysis by @OxfordEconomics, finds that the EU and UK risk falling further behind global agricultural competitors as climate & geopolitical pressures grow. Read the news here: spr.ly/6011BHycdN

Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio - bringing manufacturing closer to patients and supporting the reliable production of innovative medicines at scale. Learn more: bayer.com/media/en-us/bayer-…

#NEWS: Bayer showcases its R&D pipeline at field event in Huxley, Iowa: 10 innovations each projected to reach €500M+ in peak sales, with soy trait technology alone expected to surpass €3B. Learn more: spr.ly/6018B1CEi8

Earlier today, we published our Half Year 2026 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made last quarter and where we will put our focus for the next 90 days. Find out more: spr.ly/6013BE7fvS

Second quarter of 2026: @Bayer operationally on track to achieve full-year outlook, decisive progress on strategic priorities Here's our digital quarterly statement: spr.ly/6011BE7FqH

Earlier today, we published our Q1 2026 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made and where we will put our focus for the next 90 days. Find out more: bayer.com/en/investors-overv…

Bayer has reported a solid performance across all divisions for the first quarter and confirmed its currency-adjusted outlook for 2026. Here’s our digital quarterly statement: spr.ly/6018BBt64j

#News: We intend to acquire Perfuse Therapeutics, a biopharmaceutical company focused on ischemia-induced ocular diseases. Acquisition complements our pharmaceutical pipeline & reinforces our commitment to developing urgently needed therapies for patients: bayer.com/media/en-us/

Earlier today, we published our Full Year 2025 results. Our CEO, Bill Anderson, provides a 90-second overview of the progress we made and where we will put our focus for the next 90 days. Find out more: reports.bayer.com/annual-rep…

Bayer achieved its upgraded full-year targets for 2025 and shared the company’s outlook for 2026. Here’s our digital annual report: spr.ly/6013hfo4d


Update on Roundup Litigation: Today, a proposed U.S. nationwide class settlement was announced, designed to resolve eligible current and future RoundupTM claims through a long-term claims program. More details can be found in the link below. youtu.be/d0hIMgwy1Nw

NEW EPISODE of Long Strange Trip with Bill Anderson, CEO of @Bayer, just dropped. This episode is a master class in going Founder Mode. In 2 years he's torn down and rebuilt how a 160-year-old company operates. I hope you enjoy it. Leave a comment and let me know what struck you most.